Description
Seeking male & female patients 1-22 years of age who have been diagnosed with acute prolymphocytic leukemia (APL).
Overview
The main goal of this study is to find out if completely removing or reducing the amount of anthracycline chemotherapy used in standard APL treatment, and adding arsenic trioxide, will reduce some of the long-term side effects while maintaining a good cure rate.
What we're hoping for
We are hoping to shorten the duration of treatment and reduce the long term side effects for younger patients with relapsed B-cell acute lymphoblastic leukemia or acute prolymphocytic leukemia (APL).
Additional Information
ClinicalTrials.gov Identifier: NCT02101853